
Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target
Phathom Pharmaceuticals (PHAT) Analyst Ratings
Bulls say
Phathom Pharmaceuticals is supported by a differentiated, first-in-class P-CAB profile in VOQUEZNA, whose clinical data show rapid, durable acid suppression and strong efficacy in erosive GERD and H. pylori, including 93% healing versus 85% for lansoprazole and superior results in severe disease. The commercial thesis is strengthened by a large addressable GERD market, >80% commercial coverage, and management’s tighter GI-focused strategy after the May 2025 restructuring, with sales rising from $55MM in 2024 to 2026 guidance of $310–325MM and EBITDA profitability expected in 2026. Further upside could come from continued access improvement, a potential 2032 exclusivity runway, and pipeline expansion in EoE, where positive Phase 2 data could add another meaningful growth vector.
Bears say
Phathom Pharmaceuticals is facing a fundamentally challenged setup because VOQUEZNA’s growth has already run below the launch trajectory, with physicians still encountering access friction in a highly genericized GERD and NERD market where PPI step edits remain standard. While the company expects about $131MM of CY27 EBITDA, the thesis is pressured by modest 1H26 progress, no clear near-term upside to estimates, and a potential competing P-CAB launch in early 2027 that could dilute share and pricing. The outlook is further weakened by the exclusion of EoE from the model absent compelling 4Q26 data, plus meaningful balance-sheet risk from the $300MM secured Hercules term loan and restrictive cash covenants.
This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction
Start investing in Phathom Pharmaceuticals (PHAT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Phathom Pharmaceuticals (PHAT) Forecast
Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction
Start investing in Phathom Pharmaceuticals (PHAT)
Order type
Buy in
Order amount
Est. shares
0 shares